Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV

MK-8507 is a novel HIV-1 nonnucleoside reverse transcriptase inhibitor in clinical development with potential for once-weekly oral administration for the treatment of HIV-1 infection. Two randomized, double-blind, placebo-controlled phase 1 studies in adults without HIV-1 evaluated the safety, toler...

Descripción completa

Detalles Bibliográficos
Autores principales: Ankrom, Wendy, Jackson Rudd, Deanne, Schaeffer, Andrea, Panebianco, Deborah, Friedman, Evan J., Tomek, Charles, Stoch, S. Aubrey, Iwamoto, Marian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597757/
https://www.ncbi.nlm.nih.gov/pubmed/34516246
http://dx.doi.org/10.1128/AAC.00935-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597757/
https://www.ncbi.nlm.nih.gov/pubmed/34516246
http://dx.doi.org/10.1128/AAC.00935-21

Ejemplares similares